Pioglitazone (Actos): follow-up

The Committee for Medicinal Products for Human Use of the European Medicines Agency points out the opinion issued in July 2011 for pioglitazone. Despite the slightly increased risk of developing cancer of the bladder after taking this medicine, this remains a valid therapeutic alternative for some patients with type 2 diabetes who can not be adequately treated by other treatments (metformin).

See Press release EMA

Contact: vig@fagg-afmps.be

Last updated on
30/11/2011